Skip to content

The clinical study utilizing intestinal flora and metabolomics to investigate the efficacy of potassium sodium hydrogen citrate therapy in the treatment of uric acid kidney stones.

The clinical study utilizing intestinal flora and metabolomics to investigate the efficacy of potassium sodium hydrogen citrate therapy in the treatment of uric acid kidney stones.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077586
Enrollment
Unknown
Registered
2023-11-13
Start date
2021-12-10
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urolithiasis

Interventions

DT Group:Potassium sodium hydrogen citrate granules were used for oral stone dissolution
Control Group:None

Sponsors

Changshu Hospital affiliated to Soochow University( Changshu No. 1 People's Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: All stone patients were diagnosed using urologic ultrasonography, kidney-ureter-bladder (KUB) X-ray, or abdominal computed tomography (CT). Stone samples were obtained through ureteroscopic lithotripsy (URSL), percutaneous nephrolithotomy (PCNL), or extracorporeal shock wave lithotripsy (ESWL). Stones were analyzed using an automated infrared spectroscopy system, LIIR-20 (Lanmode Scientific Instrument Co., Ltd., Tianjin, China), and the main components were determined based on the most abundant substances listed in the report, which were classified as pure or mixed uric acid stones (anhydrous uric acid content >50%).

Exclusion criteria

Exclusion criteria: 1. Patients with malignancy, chronic liver insufficiency, a history of statin use, and thyroid or parathyroid disease were excluded from the study. 2. Participants were also excluded if they had taken antibiotics or immune suppressants within one month prior to fecal sampling, or had a history of chronic diarrhea or constipation, chronic enteritis, irritable bowel syndrome, gastrointestinal tumors or intestinal surgery.

Design outcomes

Primary

MeasureTime frame
Gut microbiota;Fecal short chain fatty acids contents;Maximum stone diameter;

Secondary

MeasureTime frame
Serum triglyceride;Total serum cholesterol;Serum high density lipoprotein cholesterol;Serum low density lipoprotein cholesterol;Serum uric acid;Serum creatinine;Serum potassium;Serum calcium;Serum magnesium;Urine ph;

Countries

China

Contacts

Public ContactCheng Cao

Changshu Hospital Affiliated to Soochow University (Changshu No.1 People's Hospital)

ak-caocheng@163.com+86 137 7177 8626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026